Department of Neurobiology, Harvard Medical School, Boston, MA, USA.
Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Epilepsia. 2018 Jan;59(1):e1-e4. doi: 10.1111/epi.13960. Epub 2017 Nov 23.
Metabolic alteration, either through the ketogenic diet (KD) or by genetic alteration of the BAD protein, can produce seizure protection in acute chemoconvulsant models of epilepsy. To assess the seizure-protective role of knocking out (KO) the Bad gene in a chronic epilepsy model, we used the Kcna1 model of epilepsy, which displays progressively increased seizure severity and recapitulates the early death seen in sudden unexplained death in epilepsy (SUDEP). Beginning on postnatal day 24 (P24), we continuously video monitored Kcna1 and Kcna1 Bad double knockout mice to assess survival and seizure severity. We found that Kcna1 Bad mice outlived Kcna1 mice by approximately 2 weeks. Kcna1 Bad mice also spent significantly less time in seizure than Kcna1 mice on P24 and the day of death, showing that BadKO provides seizure resistance in a genetic model of chronic epilepsy.
代谢改变,无论是通过生酮饮食(KD)还是通过 BAD 蛋白的基因改变,都可以在急性化学惊厥癫痫模型中产生抗惊厥保护作用。为了评估敲除 Bad 基因在慢性癫痫模型中的抗惊厥作用,我们使用了 Kcna1 癫痫模型,该模型显示癫痫严重程度逐渐增加,并重现了突发性不明原因癫痫死亡(SUDEP)中所见的早期死亡。从出生后第 24 天(P24)开始,我们连续视频监测 Kcna1 和 Kcna1 Bad 双敲除小鼠,以评估其存活率和癫痫严重程度。我们发现 Kcna1 Bad 小鼠的存活时间比 Kcna1 小鼠长约 2 周。Kcna1 Bad 小鼠在 P24 及死亡当天的癫痫发作时间也明显少于 Kcna1 小鼠,表明 BadKO 在慢性癫痫的遗传模型中提供了抗惊厥作用。